| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Immunotherapy Laboratory, Department of Immunology, and
Department of Pediatric Immunology, University Medical Center Utrecht, Utrecht, The Netherlands;
National Institute of Public Health and the Environment, Bilthoven, The Netherlands;
Department of Pathology, Faculty of Veterinary Medicine, Utrecht, The Netherlands;
¶ Department of Pathology, University of Alabama, Birmingham, AL 35487;
|| Genmab, Utrecht, The Netherlands; and
# Department of Human and Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands
Streptococcus pneumoniae is an important cause of morbitity and mortality worldwide. Capsule-specific IgG1 and IgG2 Abs are induced upon vaccination with polysaccharide-based vaccines that mediate host protection. We compared the protective capacity of human recombinant serogroup 6-specific IgG1 and IgG2 Abs in mice deficient for either leukocyte FcR or complement factors. Human IgG1 was found to interact with mouse leukocyte FcR in vitro, whereas human IgG2 did not. Both subclasses induced complement activation, resulting in C3c deposition on pneumococcal surfaces. Passive immunization of C57BL/6 mice with either subclass before intranasal challenge with serotype 6A induced similar degrees of protection. Fc
RI- and III-deficient mice, as well as the combined FcRI, II, and III knockout mice, were protected by passive immunization, indicating FcR not to be essential for protection. C1q or C2/factor B knockout mice, however, were not protected by passive immunization. Passively immunized C2/factor B-/- mice displayed higher bacteremic load than C1q-/- mice, supporting an important protective role of the alternative complement pathway. Spleens from wild-type and C1q-/- mice showed hyperemia and thrombotic vessel occlusion, as a result of septicemic shock. Notably, thrombus formation was absent in spleens of C2/factor B-/- mice, suggesting that the alternative complement pathway contributes to shock-induced intravascular coagulation. These studies demonstrate complement to play a central role in Ab-mediated protection against pneumococcal infection in vivo, as well as in bacteremia-associated thrombotic complications.
This article has been cited by other articles:
|
|
 |
|
  K. Goring, Y. Huang, C. Mowat, C. Leger, T.-H. Lim, R. Zaheer, D. Mok, L. A. Tibbles, D. Zygun, and B. W. Winston Mechanisms of human complement factor B induction in sepsis and inhibition by activated protein C Am J Physiol Cell Physiol, May 1, 2009; 296(5): C1140 - C1150. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Tian, S. Weber, P. Thorkildson, T. R. Kozel, and L.-a. Pirofski Efficacy of Opsonic and Nonopsonic Serotype 3 Pneumococcal Capsular Polysaccharide-Specific Monoclonal Antibodies against Intranasal Challenge with Streptococcus pneumoniae in Mice Infect. Immun., April 1, 2009; 77(4): 1502 - 1513. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Lu, Z. Ma, T. S. Jokiranta, A. R. Whitney, F. R. DeLeo, and J.-R. Zhang Species-Specific Interaction of Streptococcus pneumoniae with Human Complement Factor H J. Immunol., November 15, 2008; 181(10): 7138 - 7146. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. de Voer, F. R. M. van der Klis, C. W. A. M. Engels, G. T. Rijkers, E. A. Sanders, and G. A. M. Berbers Development of a Fluorescent-Bead-Based Multiplex Immunoassay To Determine Immunoglobulin G Subclass Responses to Neisseria meningitidis Serogroup A and C Polysaccharides Clin. Vaccine Immunol., August 1, 2008; 15(8): 1188 - 1193. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. O. Beenhouwer, E. M. Yoo, C.-W. Lai, M. A. Rocha, and S. L. Morrison Human Immunoglobulin G2 (IgG2) and IgG4, but Not IgG1 or IgG3, Protect Mice against Cryptococcus neoformans Infection Infect. Immun., March 1, 2007; 75(3): 1424 - 1435. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Vidarsson, A. M. Stemerding, N. M. Stapleton, S. E. Spliethoff, H. Janssen, F. E. Rebers, M. de Haas, and J. G. van de Winkel FcRn: an IgG receptor on phagocytes with a novel role in phagocytosis Blood, November 15, 2006; 108(10): 3573 - 3579. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Jonsson, V.-A. Oxelius, L. Truedsson, J. H. Braconier, G. Sturfelt, and A. G. Sjoholm Homozygosity for the IgG2 Subclass Allotype G2M(n) Protects against Severe Infection in Hereditary C2 Deficiency J. Immunol., July 1, 2006; 177(1): 722 - 728. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Burns, M. Abadi, and L.-a. Pirofski Modulation of the Lung Inflammatory Response to Serotype 8 Pneumococcal Infection by a Human Immunoglobulin M Monoclonal Antibody to Serotype 8 Capsular Polysaccharide Infect. Immun., August 1, 2005; 73(8): 4530 - 4538. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. K. Bleeker, J. J. Lammerts van Bueren, H. H. van Ojik, A. F. Gerritsen, M. Pluyter, M. Houtkamp, E. Halk, J. Goldstein, J. Schuurman, M. A. van Dijk, et al. Dual Mode of Action of a Human Anti-Epidermal Growth Factor Receptor Monoclonal Antibody for Cancer Therapy J. Immunol., October 1, 2004; 173(7): 4699 - 4707. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-S. Kang, J. Y. Kim, S. A. Bruening, M. Pack, A. Charalambous, A. Pritsker, T. M. Moran, J. M. Loeffler, R. M. Steinman, and C. G. Park The C-type lectin SIGN-R1 mediates uptake of the capsular polysaccharide of Streptococcus pneumoniae in the marginal zone of mouse spleen PNAS, January 6, 2004; 101(1): 215 - 220. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. W. Maitta, K. Datta, A. Lees, S. S. Belouski, and L.-a. Pirofski Immunogenicity and Efficacy of Cryptococcus neoformans Capsular Polysaccharide Glucuronoxylomannan Peptide Mimotope-Protein Conjugates in Human Immunoglobulin Transgenic Mice Infect. Immun., January 1, 2004; 72(1): 196 - 208. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Pleass, S. A. Ogun, D. H. McGuinness, J. G. J. van de Winkel, A. A. Holder, and J. M. Woof Novel antimalarial antibodies highlight the importance of the antibody Fc region in mediating protection Blood, December 15, 2003; 102(13): 4424 - 4430. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
